Recruiting Lymphoma Studies in Clayton
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patient...
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma....
About Lymphoma Clinical Trials in Clayton
Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.
There are currently 2 lymphoma clinical trials recruiting participants in Clayton, VICTORIA. These studies are seeking a combined 292 participants. Research is being sponsored by Innate Pharma, Novartis Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lymphoma Clinical Trials in Clayton — FAQ
Are there lymphoma clinical trials in Clayton?
Yes, there are 2 lymphoma clinical trials currently recruiting in Clayton, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Clayton?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Clayton research site will contact you about next steps.
Are clinical trials in Clayton free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Clayton studies also compensate for your time and travel.
What lymphoma treatments are being tested?
The 2 active trials in Clayton are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov